A Phase 3 interventional study of Niacin extended-release (NER) and Niacin extended-release (NER) placebo in Dyslipidemia, sponsored by Abbott. Completed at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-09.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing niacin in Dyslipidemias — none open to participants now, none under way, none of them phase 3. Niacin · Dyslipidemias.
Among the 18 studies testing niacin in Dyslipidemias, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 3, and was the 5th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 18 studies testing niacin in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
Niacin: first FDA approval 1957 (WAMPOCAP), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 276 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 30 across the 17 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
22 studies in Dyslipidemias by Abbott: none open now, none under way, none of them phase 3. Of 22 finished, 11 (50%) have results posted.
Among the 22 studies in Dyslipidemias by Abbott, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2008, is one of 15 in phase 3, and was the 16th registered.
Abbott’s Dyslipidemias studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing niacin in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 22 in Dyslipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin (ASA) daily for 6 weeks.
The FAST is a questionnaire that was developed to provide a detailed assessment of flushing symptoms and their impact in patients receiving niacin therapy. The effect of aspirin on flushing symptoms, as measured by the FAST, was also evaluated.
This study was designed to evaluate the psychometric characteristics of the FAST questionnaire.
The FAST is a self-administered questionnaire, completed using a hand-held electronic data capture device (LogPad e-diary). Subjects recorded the start and stop date and time of each flushing event, the presence and severity of individual flushing symptoms (redness, warmth, tingling and/or itching), and an overall assessment of their flushing experience.
Evaluation of the psychometric characteristics of the FAST was based on 3 primary data analyses: 1 ) test-retest reliability based on the intraclass correlation coefficient; 2) construct validity based on Spearman correlation coefficients; and 3) responsiveness based on changes in FAST scores. The mean and maximum severity of flushing events, as measured by the FAST, were the primary variables evaluated in each of the 3 data analyses mentioned above. Psychometric analyses were performed blinded to treatment group assignment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Niacin extended-release (NER) · Drug: Aspirin (ASA)
Drug: Niacin extended-release (NER) · Drug: Aspirin (ASA) placebo
Drug: Niacin extended-release (NER) placebo · Drug: Aspirin (ASA) placebo
Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
Also known as: ABT-919, Niaspan
Tablets administered once daily for 6 weeks
Tablets (325 mg) administered once daily for 6 weeks
Also known as: acetylsalicylic acid
Tablets administered once daily for 6 weeks
Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score
Test-retest reliability of the mean flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.
Time frame: Week 1 to Week 2
FAST Test-retest Reliability--maximum Flushing Severity Score
Test-retest reliability of the maximum flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.
Time frame: Week 1 to Week 2
FAST Cross-sectional Construct Validity--mean Flushing Severity Score
The relationship between mean flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.
Time frame: Week 1
FAST Cross-sectional Construct Validity--maximum Flushing Severity Score
The relationship between maximum flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.
Time frame: Week 1
FAST Longitudinal Construct Validity--mean Flushing Severity Score
The relationship between the change in mean flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).
Time frame: Week 1 to Week 2
FAST Longitudinal Construct Validity--maximum Flushing Severity Score
The relationship between the change in maximum flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).
Time frame: Week 1 to Week 2
FAST Responsiveness--mean Flushing Severity Score
The change in mean flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in mean flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.
Time frame: Study start to Day 43
FAST Responsiveness--maximum Flushing Severity Score
The change in maximum flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in maximum flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.
Time frame: Study start to Day 43
Maximum Severity of Flushing Events Overall During the Study
The severity of flushing events was assessed as none, mild, moderate, severe, or very severe using the FAST. The maximum severity of flushing events overall during the study was compared among treatment groups.
Time frame: Week 1 to Week 6
Subjects were enrolled at 41 sites in the United States between February and June, 2008.
| Milestone | NER/ASA | NER/ASA Placebo | NER Placebo/ASA Placebo |
|---|---|---|---|
| Started | 91 | 90 | 90 |
| Completed | 72 | 75 | 80 |
| Not completed | 19 | 15 | 10 |
| Withdrew: Adverse event | 11 | 8 | 7 |
| Withdrew: Withdrawal by subject | 3 | 4 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Noncompliance | 2 | 3 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Personal reasons | 0 | 0 | 1 |
Test-retest reliability of the mean flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.
| Intraclass correlation coefficient | Subjects With Stable Flushing Symptoms |
|---|---|
| Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score | 0.75 |
The severity of flushing events was assessed as none, mild, moderate, severe, or very severe using the FAST. The maximum severity of flushing events overall during the study was compared among treatment groups.
| Percentage of subjects | NER/ASA | NER/ASA Placebo | NER Placebo/ASA Placebo |
|---|---|---|---|
| None | 26 | 14 | 37 |
| Mild | 23 | 16 | 38 |
| None/Mild | 49 | 30 | 75 |
| Moderate | 34 | 31 | 22 |
| Severe | 17 | 32 | 2 |
| Very Severe | 0 | 7 | 0 |
Test-retest reliability of the maximum flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.
| Intraclass correlation coefficient | Subjects With Stable Flushing Symptoms |
|---|---|
| FAST Test-retest Reliability--maximum Flushing Severity Score | 0.40 |
The relationship between mean flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.
| Spearman correlation coefficient | Modified Intent-to-Treat (m-ITT) Population |
|---|---|
| FAST Cross-sectional Construct Validity--mean Flushing Severity Score | 0.64 |
The relationship between maximum flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.
| Spearman correlation coefficient | Modified Intent-to-Treat (m-ITT) Population |
|---|---|
| FAST Cross-sectional Construct Validity--maximum Flushing Severity Score | 0.66 |
The relationship between the change in mean flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).
| Spearman correlation coefficient | Modified Intent-to-Treat (m-ITT) Population |
|---|---|
| FAST Longitudinal Construct Validity--mean Flushing Severity Score | -0.44 |
The relationship between the change in maximum flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).
| Spearman correlation coefficient | Modified Intent-to-Treat (m-ITT) Population |
|---|---|
| FAST Longitudinal Construct Validity--maximum Flushing Severity Score | -0.42 |
The change in mean flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in mean flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.
| Units on a scale | Responders | Nonresponders |
|---|---|---|
| FAST Responsiveness--mean Flushing Severity Score | -0.51 | 0.15 |
The change in maximum flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in maximum flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.
| Units on a scale | Responders | Nonresponders |
|---|---|---|
| FAST Responsiveness--maximum Flushing Severity Score | -1.85 | -0.18 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NER/ASA | — | — | — |
| NER/ASA Placebo | — | — | — |
| NER Placebo/ASA Placebo | — | — | — |
| Event | NER/ASA | NER/ASA Placebo | NER Placebo/ASA Placebo |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/91 | 1/90 | 0/90 |
| Right renal cystRenal and urinary disorders | 0/91 | 0/90 | 1/90 |
| NephrolithiasisRenal and urinary disorders | 0/91 | 0/90 | 1/90 |
| Adenomatous polyposisCongenital, familial and genetic disorders | 0/91 | 0/90 | 1/90 |
| Non-cardiac chest painGeneral disorders | 1/91 | 0/90 | 0/90 |
| Event | NER/ASA | NER/ASA Placebo | NER Placebo/ASA Placebo |
|---|---|---|---|
| FlushingVascular disorders | 68/91 | 78/90 | 56/90 |
| DiarrheaGastrointestinal disorders | 2/91 | 7/90 | 5/90 |
| HeadacheNervous system disorders | 3/91 | 1/90 | 7/90 |
| NauseaGastrointestinal disorders | 4/91 | 2/90 | 2/90 |
| VomitingGastrointestinal disorders | 3/91 | 2/90 | 2/90 |
| Upper respiratory tract infectionInfections and infestations | 3/91 | 2/90 | 2/90 |
| FatigueGeneral disorders | 1/91 | 2/90 | 0/90 |
| SinusitisInfections and infestations | 1/91 | 2/90 | 1/90 |
| HyperglycemiaMetabolism and nutrition disorders | 0/91 | 2/90 | 0/90 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/91 | 2/90 | 0/90 |
| Age Continuous(years) | NER/ASA | NER/ASA Placebo | NER Placebo/ASA Placebo | Total |
|---|---|---|---|---|
| Mean | 54.1 ± 11.68 | 53.7 ± 12.74 | 52.9 ± 12.26 | 53.6 ± 12.20 |
| Sex: Female, Male(Participants) | NER/ASA | NER/ASA Placebo | NER Placebo/ASA Placebo | Total |
|---|---|---|---|---|
| Female | 42 | 41 | 42 | 125 |
| Male | 49 | 49 | 48 | 146 |
| Region of Enrollment(participants) | NER/ASA | NER/ASA Placebo | NER Placebo/ASA Placebo | Total |
|---|---|---|---|---|
| United States | 91 | 90 | 90 | 271 |
The record gives a start of Feb 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niacin · Aspirin